Testing effectiveness (Phase 2)Not Yet RecruitingNCT06652685
What this trial is testing
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Who this might be right for
Acute Myeloid Leukemia (AML)
Ruijin Hospital 218